IGLL5 (Immunoglobulin Lambda Like Polypeptide 5)

Clinically, blocking IGLL5 preserves TLSs and enhances immunotherapy efficacy in patient-derived xenograft (PDX) and pan-cancer models. Our findings suggest that targeting IGLL5+ B cells offers a promising strategy to boost TLS-dependent cancer immunotherapy.

Docking yielded negative free energies compatible with interference in immune signaling.ConclusionsThis integrative analysis connected environmental toxicology to tumor immunity and nominated CCL19, CD40LG, IGLL5, and KLRB1 as candidate biomarkers for exposure-risk assessment. The findings are correlative and require mechanistic validation.

In three MAG neuropathy patients we find evidence that the self-reactive B cells responsible for their disease acquired a classical lymphoma driver somatic mutation early in their clonal expansion.

However, limitations include the lack of immune cell co-culture models and in vivo validation. This study provides essential insights into the immunotoxicity of PET-MPs and highlights the need for further research to explore their direct and indirect effects on cancer development.

IGLL5 is a novel prognostic marker for BRCA, and its expression level affects patient survival by modulating TME immune infiltration and metabolic reprogramming. This study provides a theoretical basis for IGLL5-directed immunotherapeutic strategies (e.g., combining PD-1 inhibitors), and its mechanism needs to be verified by multicenter clinical cohorts and functional experiments in the future.

No significant difference was found in the overall survival between CD10-MUM1+ FL and conventional FL patients. In summary, this study demonstrated that CD10-MUM1+ FL has unique clinical, pathological ​and genetic features.

Group 4, which included patients with PVT1::IGLL5 fusion, had the poorest prognosis. In conclusion, Blina and InO showed specific treatment advantages for different patient groups in our cohort that may be attributed to intrinsic genetic characteristics, such as new fusion genes.

In summary, we characterized the genomic landscape of MM in diverse Chinese populations, confirmed clonal evolution, and identified prognostic genes.

Additionally, we identified 11 differentially expressed genes that could provide insights into the potential mechanisms of immune escape in patients with lung cancer. These findings offer promising molecular targets for the detection and treatment of immune escape in clinical settings.

Finally, a ctDNA-based risk model was built based on the above independent risk factors, which serves as an adjunct non-invasive measure of substantial tumor burden and a prognostic genetic feature that can assist in predicting the response to anti-BCMA CAR-T therapy.

The state-of-the-art Nanopore direct-RNA sequencing and machine learning techniques enables comprehensive identification of m6A modification and provided insights into the potential post-transcriptional regulation mechanisms on the development and progression in MIBC.

IGLL5, MYD88, and KMT2D mutations were enriched in Taiwanese CLL, and co-occurrence of MYD88 mutations with KMT2D or/and IGLL5 mutations was associated with a poorer prognosis.